Pascalis Fabian, NIM011511133035 (2018) POLA RESISTENSI BAKTERI PSEUDOMONAS AERUGINOSA DAN ACINETOBACTER BAUMANNII PADA SPESIMEN DARAH TERHADAP ANTIBIOTIK GOLONGAN β-LAKTAM DAN AMINOGLIKOSIDA DI RUMAH SAKIT DR. SOETOMO PERIODE JANUARI 2016 – DESEMBER 2016. Skripsi thesis, Universitas Airlangga.

	Text (ABSTRAK) FK PD 167-18 Fab p abstrak.pdf Download (348kB)
	Text (FULLTEXT) FK PD 167-18 Fab p.pdf Restricted to Registered users only until January 2022. Download (1MB) | Request a copy

Abstract

Pseudomonas aeruginosa and Acinetobacter baumannii are one of the causes of bacterial infection in the hospital. All throughout the world there had been cases of which those bacterias have developed resistance to antibiotics. This descriptive study was aimed towards finding the resistance pattern of Pseudomonas aeruginosa and Acinetobacter baumannii to antibiotics treatment, specifically from the β-lactam group and aminoglycoside group. Data wass cited from the isolate logbook of the Department of Clinical Microbiology of Dr. Soetomo General and Teaching Hospital within January 2016 – December 2016. The results from 63 samples for Pseudomonas aeruginosa showed that the most susceptible age groups were within 0-5 years of age (38%) followed by age >45 years (23,8%). Whereas the results from 164 samples for Acinetobacter baumannii the most susceptible age groups were also within 5 years of age (32,9%) followed by age >45 years (29,9%). According to gender, the Pseudomonas aeruginosa samples were 55,5% male and 45,5% female. For Acinetobacter baumannii the samples were 51,2% male and 48,8% female. Resistance patterns showed that Pseudomonas aeruginosa was resistant to ceftazidime (27,4%), gentamicin (24,1%), imipenem (14%), meropenem (11,7%), dan amikacin (4,9%). Acinetobacter baumannii was resistant to ceftazidime (78,8%), gentamicin (70,1%), amikacin (51,2%), imipenem (49,3%), and meropenem (48,1%),. In conclusion, both Pseudomonas aeruginosa and Acinetobacter baumannii had shown resistance towards antibiotics, in particular towards ceftazidime, imipenem, meropenem, gentamicin, and amikacin.

Actions (login required)

View Item